> d l7
L7 HAS NO ANSWERS
L7 STR



NODE ATTRIBUTES:
NSPEC IS R AT 9
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 1
NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE

=> d his l9

(FILE 'REGISTRY' ENTERED AT 17:22:14 ON 20 AUG 2007)
L9 829 S L7 FUL

=> s l9 and (piperidin? or piperazin?)
1182137 PIPERIDIN?
887543 PIPERAZIN?
L12 757 L9 AND (PIPERIDIN? OR PIPERAZIN?)

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	10.35	259.99

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-10.14

FILE 'CAPLUS' ENTERED AT 17:31:23 ON 20 AUG 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 Aug 2007 VOL 147 ISS 9
FILE LAST UPDATED: 19 Aug 2007 (20070819/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l12
L13 7 L12

=> d l1

L1 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:591177 CAPLUS
DN 139:149652
TI Preparation of 2-acylaminothiazole derivatives or salts thereof as c-Mpl receptor ligands
IN Sugasawa, Keizo; Watanuki, Susumu; Koga, Yuji; Nagata, Hiroshi; Obitsu, Kazuyoshi; Wakayama, Ryutaro; Hirayama, Fukushi; Suzuki, Ken-ichi
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 110 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003062233	A1	20030731	WO 2003-JP270	20030115 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2472711	A1	20030731	CA 2003-2472711	20030115
	EP 1466912	A1	20041013	EP 2003-700571	20030115
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1639157	A	20050713	CN 2003-804457	20030115
	IN 2004KN00942	A	20060217	IN 2004-KN942	20040705
	US 2005153977	A1	20050714	US 2004-500964	20040708
PRAI	JP 2002-10413	A	20020118		
	JP 2002-10447	A	20020118		
	WO 2003-JP270	W	20030115		

OS MARPAT 139:149652
RE.CNT 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l13 not l1
L14 6 L13 NOT L1

=> d bib abs 1-6

L14 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:538881 CAPLUS
DN 146:528295
TI Compositions and methods for treating thrombocytopenia
IN Suzuki, Ken-Ichi; Sugasawa, Keizo
PA Astellas Pharma Inc., Japan
SO PCT Int. Appl., 47pp.
CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007054783	A2	20070518	WO 2006-IB3142	20061107

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI US 2005-734426P P 20051108
OS MARPAT 146:528295
AB The present invention in certain embodiments is directed to a pharmaceutical dosage form comprising a therapeutically effective amount of a first agent that agonizes a human TPO receptor by binding to the rhTPO binding site of the human TPO receptor; and a therapeutically effective amount of a second agent that agonizes the human TPO receptor by binding to a binding site of the human TPO receptor distinct from the rhTPO binding site.

L14 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2007:150903 CAPLUS
DN 146:229330
TI Preparation of thiazole derivatives as agents for treating and/or preventing sleep disorder
IN Uesaka, Noriaki; Ichikawa, Shunji; Nakajima, Takao
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 256pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2007015528	A1	20070208	WO 2006-JP315328	20060802

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI JP 2005-223547 A 20050802
OS MARPAT 146:229330
GI



I

AB The title compds. I [R1 = (un)substituted five-membered aromatic heterocyclic group containing at least one oxygen atom; R2 = halo; (un)substituted alkyl, (un)substituted alkenyl, etc.; R3 = NR10R11, CONHR16, etc.; R10, R11 = H, (un)substituted alkyl, (un)substituted alkenyl, etc.; R16 = H, (un)substituted alkyl, (un)substituted alkenyl, etc.] are prepared Thus, 2-(benzimidazol-2-yl)-4-(2-furyl)thiazol-5-yl tetrahydropyran-4-yl ketone was prepared in 2 steps from Me tetrahydropyran-4-carboxylate and N,O-dimethylhydroxylamine hydrochloride. In a test using mice, compds. of this invention at 10 mg/kg orally significantly reduced the pentobarbital sodium-induced sleeping time. Formulations are given.

RE.CNT 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:612283 CAPLUS
DN 143:133362
TI Synthesis of Thiazole derivatives for adenosine A2A receptor antagonist
IN Nakajima, Takao; Sugawara, Masamori; Uchida, Shinichi; Ohno, Tetsuji; Nomoto, Yuji; Uesaka, Noriaki; Nakasato, Yoshisuke
PA Kyowa Hakko Kogyo Co., Ltd., Japan
SO PCT Int. Appl., 394 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005063743	A1	20050714	WO 2004-JP19778	20041224
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004309279	A1	20050714	AU 2004-309279	20041224
	CA 2551611	A1	20050714	CA 2004-2551611	20041224
	EP 1700856	A1	20060913	EP 2004-808128	20041224
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
	CN 1902196	A	20070124	CN 2004-80038930	20041224
	BR 2004018082	A	20070417	BR 2004-18082	20041224
	MX 2006PA07357	A	20060913	MX 2006-PA7357	20060623
	US 2007105919	A1	20070510	US 2006-584633	20060626
	IN 2006CN02747	A	20070608	IN 2006-CN2747	20060725
	NO 2006003446	A	20060908	NO 2006-3446	20060726
PRAI	JP 2003-432777	A	20031226		
	WO 2004-JP19778	W	20041224		

OS MARPAT 143:133362
GI



I

AB The patent relates to the synthesis of an adenosine A2A receptor antagonist which contains as an active ingredient either a thiazole derivative represented by I (wherein n is an integer of 0 to 3; R1 represents (un)substituted cycloalkyl, (un)substituted aryl, (un)substituted alicyclic heterocyclic group, or (un)substituted aromatic heterocyclic group; R2 represents halogeno, (un)substituted lower alkyl, (un)substituted aryl, (un)substituted alicyclic heterocyclic group, (un)substituted aromatic heterocyclic group, -COR8, etc.; and R3 and R4 are the same or different and each represents hydrogen, (un)substituted lower alkyl, (un)substituted aralkyl, -COR12, etc.) or a pharmacol. acceptable salt of the derivative Thus, N-[4-(2-furyl)-5-(4-pyridyl)thiazol-2-yl]pyridine-4-carboxyamide (40 gm) was prepared and formulated with lactose 286.8, potato starch 60, hydeoypropylcellulose (10% aqueous solution) 120, and magnesium stearate 1.2 gm to make tablets containing 10% active ingredient for adenosine A2A receptor antagonist.

RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:287844 CAPLUS
DN 140:321382
TI Preparation of maleic acid salt of 2-acylaminothiazole derivative
IN Sugasawa, Keizo; Koga, Yuji; Hirayama, Fukushi; Suzuki, Ken-ichi; Awamura, Yuuji
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004029049	A1	20040408	WO 2003-JP12419	20030929
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003268687	A1	20040419	AU 2003-268687	20030929
PRAI	JP 2002-284689	A	20020930		
	WO 2003-JP12419	W	20030929		

GI



I

AB Disclosed are maleic acid salt of 1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid (I), which is useful as a remedy for thrombopenia, and drugs, in particular platelet-increasing agent and/or a remedy for thrombopenia, containing this compound as the active ingredient. Thus, bromination of 4-chloro-2-acetylthiophene by Br in Et2O followed by cyclocondensation with thiourea in EtOH at 80° overnight gave 2-amino-4-(4-chlorothiophen-2-yl)thiazole which underwent bromination with N-bromosuccinimide in DMF under ice-cooing for 20 min and amination with 4-cyclohexylpiperazine in the presence of Et3N at 70° for 3 days to give 2-amino-4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazole (II). Amidation of II with 5,6-dichloronicotinic acid using POCl3 in pyridine at room temperature for 4 h gave 5,6-dichloro-N-[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]nicotinamide which underwent amination with Et isonipecotate in THF at 50° for 5 h to give 1-[3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)thiazol-2-yl]carbamoyl]pyridin-2-yl]piperidine-4-carboxylic acid Et ester (III). Saponification of III with a mixture of 1 M aqueous NaOH solution and ethanol followed by treatment with maleic acid gave I maleic acid salt which in vitro at 3.3 nM promoted the proliferation of human c-mpl-Ba/F3 cells with a comparable efficacy as that of rhTPO.

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:615589 CAPLUS
DN 137:169545
TI Preparation of 2-acylaminothiazole derivatives or their salts as promoters of megakaryocyte colony formation
IN Koshio, Hiroyuki; Kimizuka, Tetsuya; Sugasawa, Keizo; Watanuki, Susumu; Koga, Yuji; Nagata, Hiroshi; Suzuki, Kenichi; Abe, Masaki
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002062775	A1	20020815	WO 2002-JP755	20020131

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

	AU 2002230110	A1	20020819	AU 2002-230110	20020131
	EP 1357116	A1	20031029	EP 2002-711252	20020131
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004077697	A1	20040422	US 2003-470917	20030801
PRAI	JP 2001-26955	A	20010202		
	WO 2002-JP755	W	20020131		

OS MARPAT 137:169545

GI



I

AB The title compds. [I; Ar = Ph or pyridinyl optionally substituted by ≥1 group(s) selected from lower alkyl, lower alkylcarbonyl, lower alkoxycarbonyl, HO, lower alkoxy, lower alkylcarbonyloxy, and halo; R1 = aryl or pyridyl optionally substituted by ≥1 group(s) selected from lower alkyl, lower alkylcarbonyl, lower alkoxycarbonyl, HO, lower alkoxy, lower alkylcarbonyloxy, and halo; R2 = H, OH, CO2H, lower alkyloxycarbonyl, mono- or di(lower alkyl)carbamoyl, amino, or cyclic amino, wherein more than 1 of R2 may be present; X = CH2, O, S, NR3; R3 = (un)substituted lower alkyl, cycloalkyl, (un)substituted aryl, (un)substituted aryl-lower alkyl, (un)substituted heteroaryl, (un)substituted heteroaryl-lower alkyl, lower alkylcarbonyl, lower alkoxycarbonyl, mono- or di(lower alkyl)carbamoyl] or pharmaceutically acceptable salts thereof are prepared These compds. I have an activity of increasing platelets based on an excellent effect of accelerating megakaryocyte colony formation and are efficacious in treating thrombopenia. Thus, 680 mg 2-methoxyisonicotinic acid and 1.02 g 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride were added to a solution of 1.60 g 2-amino-4-(4-fluorophenyl)-5-(4-cyclohexylpiperazino)thiazole in 30 mL THF and stirred at room temperature for 4 days to give N-[5-(4-cyclohexylpiperazi-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-2-methoxyisonicotinamide hydrochloride (II). II in vitro increased the formation of megakaryocyte colonies of human CD34+ cells from 5.2 at 0.3 μM to 19.0 and 34.8 at 1.0 and 3.0 μM, resp.

RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1993:449382 CAPLUS

DN 119:49382

TI preparation of 2-(2-indolylcarbonylamino)thiazoles and analogs as CCK and gastrin antagonists

IN Boigegrain, Robert; Brodin, Roger; Gully, Danielle; Molimard, Jean Charles; Olliero, Dominique

PA Elf Sanofi SA, Fr.

SO Eur. Pat. Appl., 51 pp.
CODEN: EPXXDW

DT Patent

LA French

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 518731	A1	19921216	EP 1992-401518	19920603
	EP 518731	B1	19980826		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, PT, SE				
	FR 2677356	A1	19921211	FR 1991-6814	19910605
	FR 2677356	B1	19950317		
	IL 102004	A	19970415	IL 1992-102004	19920526
	AU 9217279	A	19921210	AU 1992-17279	19920528
	AU 650754	B2	19940630		
	US 5314889	A	19940524	US 1992-889910	19920529
	ZA 9203981	A	19931201	ZA 1992-3981	19920601
	AT 170186	T	19980915	AT 1992-401518	19920603
	ES 2121575	T3	19981201	ES 1992-401518	19920603
	CA 2070526	A1	19921206	CA 1992-2070526	19920604
	NO 9202215	A	19921207	NO 1992-2215	19920604
	NO 300135	B1	19970414		
	JP 05155871	A	19930622	JP 1992-144150	19920604
	JP 3199451	B2	20010820		
	RU 2059637	C1	19960510	RU 1992-5011874	19920604
	HU 75870	A2	19970528	HU 1992-1870	19920604
	HU 221312	B1	20020928		
	CZ 289003	B6	20011017	CZ 1992-1693	19920604
	BR 9202156	A	19930202	BR 1992-2156	19920605
	KR 222309	B1	19991001	KR 1992-9859	19920605
	US 5380736	A	19950110	US 1994-205408	19940303
	HK 1012397	A1	20000519	HK 1998-113673	19981216
PRAI	FR 1991-6814	A	19910605		
	US 1992-889910	A3	19920529		

OS MARPAT 119:49382

GI



I



II

AB Title compds. [I; R = heterocyclyl; R1 = H, alkyl, phenylalkyl, aminoalkyl, etc.; R4 = cycloalkyl, Ph, etc.; R5 = (CH2)mX, alkoxy, OH, etc.; X = H, OH, cycloalkyl, alkoxycarbonyl, etc.; m = 0-5] were prepared Thus, 2,4-(MeO)2C6H3COCHBrCH2Ph was cyclocondensed with H2NCSNH2 and the product condensed with 1-acetylindole-2-carboxylic acid to give, after deprotection, title compound II. I had IC50 of 10-6 to 10-9 M against CCK 8S-stimulated amylase secretion by monkey pancreatic tissue.

AN 2002:615589 CAPLUS
DN 137:169545
TI Preparation of 2-acylaminothiazole derivatives or their salts as promoters of megakaryocyte colony formation
IN Koshio, Hiroyuki; Kimizuka, Tetsuya; Sugasawa, Keizo; Watanuki, Susumu; Koga, Yuji; Nagata, Hiroshi; Suzuki, Kenichi; Abe, Masaki
PA Yamanouchi Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062775	A1	20020815	WO 2002-JP755	20020131
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002230110	A1	20020819	AU 2002-230110	20020131
	EP 1357116	A1	20031029	EP 2002-711252	20020131
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2004077697	A1	20040422	US 2003-470917	20030801
PRAI	JP 2001-26955	A	20010202		
	WO 2002-JP755	W	20020131		

OS MARPAT 137:169545
IT 446065-73-2P, N-[5-(4-Cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-2-methoxyisonicotinamide hydrochloride 446065-74-3P, 3-Chloro-N-[5-(4-cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-4-hydroxybenzamide hydrochloride 446065-75-4P, 1-[2-[(3,5-Dimethoxybenzoyl)amino]-4-phenylthiazol-5-yl]piperidine-4-carboxylic acid 446065-76-5P, N-[5-(4-Cyclohexylpiperazin-1-yl)-4-phenylthiazol-2-yl]-4-hydroxybenzamide dihydrochloride 446065-77-6P, N-[5-(3-Carboxypiperidin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide 446065-78-7P, N-[5-(4-Ethoxycarbonylpiperidin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide 446065-79-8P, N-[5-(3-Ethoxycarbonylpiperidin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide 446065-82-3P, N-[5-(Piperidin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446065-83-4P, N-[5-(4-Methylpiperazin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446065-84-5P, N-[5-(4-Hydroxypiperidin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446065-85-6P, N-[5-(3-Hydroxypiperidin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446065-86-7P, N-[5-(3-Carbamoylpiperidin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446065-87-8P, N-[5-(3-(Diethylcarbamoyl)piperidin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446065-88-9P, N-[5-(4-Ethylpiperazin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446065-89-0P, N-[5-(4-Propylpiperazin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446065-90-3P, N-[5-(4-Cyclopropylpiperazin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446065-91-4P, N-[5-(4-Cyclohexylpiperazin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446065-92-5P, N-[5-(4-Phenylpiperazin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide

hydrochloride 446065-93-6P, N-[5-(4-Benzylpiperazin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446065-94-7P, N-[5-(4-(2-Methoxyethyl)piperazin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446065-95-8P, N-[5-(4-(2-Phenoxyethyl)piperazin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446065-96-9P, N-[5-(4-(Pyrrolidin-1-yl)piperidin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446065-97-0P, N-[5-(4-(Piperidin-1-yl)piperidin-1-yl)-4-phenylthiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446066-00-8P, N-[5-(Piperidin-1-yl)-4-(4-pyridyl)thiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446066-01-9P, N-[5-(Piperidin-1-yl)-4-(3-pyridyl)thiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446066-02-0P, N-[5-(Piperidin-1-yl)-4-(2-pyridyl)thiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446066-03-1P, N-[5-(4-Cyclohexylpiperazin-1-yl)-4-(4-hydroxyphenyl)thiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446066-04-2P, N-[5-(4-Cyclohexylpiperazin-1-yl)-4-(3-hydroxyphenyl)thiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446066-05-3P, N-[5-(4-Cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446066-06-4P, N-[5-(4-Cyclohexylpiperazin-1-yl)-4-(3-fluorophenyl)thiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446066-07-5P, N-[5-(4-Cyclohexylpiperazin-1-yl)-4-(2-fluorophenyl)thiazol-2-yl]-3,5-dimethoxybenzamide hydrochloride 446066-08-6P, N-[5-(4-Cyclohexylpiperazin-1-yl)-4-phenylthiazol-2-yl]-2-methoxypyridine-4-carboxamide hydrochloride 446066-09-7P, N-[5-(4-Cyclohexylpiperazin-1-yl)-4-phenylthiazol-2-yl]-4-acetoxybenzamide hydrochloride 446066-10-0P, N-[5-(4-Cyclohexylpiperazin-1-yl)-4-(3-hydroxyphenyl)thiazol-2-yl]-2-methoxypyridine-4-carboxamide hydrochloride 446066-12-2P, N-[5-(4-Cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-2-methoxyisonicotinamide 446066-13-3P, 3-Chloro-N-[5-(4-cyclohexylpiperazin-1-yl)-4-(4-fluorophenyl)thiazol-2-yl]-4-hydroxybenzamide 446066-14-4P, 3,5-Dimethoxy-N-(5-(piperidin-1-yl)-4-(4-pyridyl)thiazol-2-yl)benzamide 446066-15-5P, 4-[[5-(4-Cyclohexylpiperazin-1-yl)-4-phenylthiazol-2-yl]carbamoyl]phenyl acetate
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylaminothiazole derivs. or salts as promoters of megakaryocyte colony formation for increasing blood platelets and treating thrombopenia)

RN 446065-73-2 CAPLUS

CN 4-Pyridinecarboxamide, N-[5-(4-cyclohexyl-1-piperazinyl)-4-(4-fluorophenyl)-2-thiazolyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446065-74-3 CAPLUS
CN Benzamide, 3-chloro-N-[5-(4-cyclohexyl-1-piperazinyl)-4-(4-fluorophenyl)-2-thiazolyl]-4-hydroxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446065-75-4 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[(3,5-dimethoxybenzoyl)amino]-4-phenyl-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 446065-76-5 CAPLUS
CN Benzamide, N-[5-(4-cyclohexyl-1-piperazinyl)-4-phenyl-2-thiazolyl]-4-hydroxy-, dihydrochloride (9CI) (CA INDEX NAME)



● 2 HCl

RN 446065-77-6 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[2-[(3,5-dimethoxybenzoyl)amino]-4-phenyl-5-thiazolyl]- (9CI) (CA INDEX NAME)



RN 446065-78-7 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[2-[(3,5-dimethoxybenzoyl)amino]-4-phenyl-5-thiazolyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 446065-79-8 CAPLUS
CN 3-Piperidinecarboxylic acid, 1-[2-[(3,5-dimethoxybenzoyl)amino]-4-phenyl-5-thiazolyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 446065-82-3 CAPLUS
CN Benzamide, 3,5-dimethoxy-N-[4-phenyl-5-(1-piperidinyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446065-83-4 CAPLUS
CN Benzamide, 3,5-dimethoxy-N-[5-(4-methyl-1-piperazinyl)-4-phenyl-2-

thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446065-84-5 CAPLUS
CN Benzamide, N-[5-(4-hydroxy-1-piperidinyl)-4-phenyl-2-thiazolyl]-3,5-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446065-85-6 CAPLUS
CN Benzamide, N-[5-(3-hydroxy-1-piperidinyl)-4-phenyl-2-thiazolyl]-3,5-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446065-86-7 CAPLUS
CN 3-Piperidinecarboxamide, 1-[2-[(3,5-dimethoxybenzoyl)amino]-4-phenyl-5-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446065-87-8 CAPLUS
CN 3-Piperidinecarboxamide, 1-[2-[(3,5-dimethoxybenzoyl)amino]-4-phenyl-5-thiazolyl]-N,N-diethyl-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446065-88-9 CAPLUS
CN Benzamide, N-[5-(4-ethyl-1-piperazinyl)-4-phenyl-2-thiazolyl]-3,5-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446065-89-0 CAPLUS
CN Benzamide, 3,5-dimethoxy-N-[4-phenyl-5-(4-propyl-1-piperazinyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446065-90-3 CAPLUS
CN Benzamide, N-[5-(4-cyclopropyl-1-piperazinyl)-4-phenyl-2-thiazolyl]-3,5-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446065-91-4 CAPLUS
CN Benzamide, N-[5-(4-cyclohexyl-1-piperazinyl)-4-phenyl-2-thiazolyl]-3,5-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446065-92-5 CAPLUS
CN Benzamide, 3,5-dimethoxy-N-[4-phenyl-5-(4-phenyl-1-piperazinyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446065-93-6 CAPLUS
CN Benzamide, 3,5-dimethoxy-N-[4-phenyl-5-[4-(phenylmethyl)-1-piperazinyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446065-94-7 CAPLUS
CN Benzamide, 3,5-dimethoxy-N-[5-[4-(2-methoxyethyl)-1-piperazinyl]-4-phenyl-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446065-95-8 CAPLUS
CN Benzamide, 3,5-dimethoxy-N-[5-[4-(2-phenoxyethyl)-1-piperazinyl]-4-phenyl-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446065-96-9 CAPLUS
CN Benzamide, 3,5-dimethoxy-N-[4-phenyl-5-[4-(1-pyrrolidinyl)-1-piperidinyl]-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446065-97-0 CAPLUS
CN Benzamide, N-(5-[1,4'-bipiperidin]-1'-yl-4-phenyl-2-thiazolyl)-3,5-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446066-00-8 CAPLUS
CN Benzamide, 3,5-dimethoxy-N-[5-(1-piperidinyl)-4-(4-pyridinyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446066-01-9 CAPLUS
CN Benzamide, 3,5-dimethoxy-N-[5-(1-piperidinyl)-4-(3-pyridinyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446066-02-0 CAPLUS
CN Benzamide, 3,5-dimethoxy-N-[5-(1-piperidinyl)-4-(2-pyridinyl)-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446066-03-1 CAPLUS
CN Benzamide, N-[5-(4-cyclohexyl-1-piperazinyl)-4-(4-hydroxyphenyl)-2-thiazolyl]-3,5-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446066-04-2 CAPLUS
CN Benzamide, N-[5-(4-cyclohexyl-1-piperazinyl)-4-(3-hydroxyphenyl)-2-thiazolyl]-3,5-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446066-05-3 CAPLUS
CN Benzamide, N-[5-(4-cyclohexyl-1-piperazinyl)-4-(4-fluorophenyl)-2-thiazolyl]-3,5-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446066-06-4 CAPLUS
CN Benzamide, N-[5-(4-cyclohexyl-1-piperazinyl)-4-(3-fluorophenyl)-2-thiazolyl]-3,5-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446066-07-5 CAPLUS
CN Benzamide, N-[5-(4-cyclohexyl-1-piperazinyl)-4-(2-fluorophenyl)-2-thiazolyl]-3,5-dimethoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446066-08-6 CAPLUS
CN 4-Pyridinecarboxamide, N-[5-(4-cyclohexyl-1-piperazinyl)-4-phenyl-2-thiazolyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446066-09-7 CAPLUS
CN Benzamide, 4-(acetyloxy)-N-[5-(4-cyclohexyl-1-piperazinyl)-4-phenyl-2-thiazolyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446066-10-0 CAPLUS
CN 4-Pyridinecarboxamide, N-[5-(4-cyclohexyl-1-piperazinyl)-4-(3-hydroxyphenyl)-2-thiazolyl]-2-methoxy-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 446066-12-2 CAPLUS
CN 4-Pyridinecarboxamide, N-[5-(4-cyclohexyl-1-piperazinyl)-4-(4-fluorophenyl)-2-thiazolyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 446066-13-3 CAPLUS
CN Benzamide, 3-chloro-N-[5-(4-cyclohexyl-1-piperazinyl)-4-(4-fluorophenyl)-2-thiazolyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 446066-14-4 CAPLUS
CN Benzamide, 3,5-dimethoxy-N-[5-(1-piperidinyl)-4-(4-pyridinyl)-2-thiazolyl]- (9CI) (CA INDEX NAME)



RN 446066-15-5 CAPLUS
CN Benzamide, 4-(acetyloxy)-N-[5-(4-cyclohexyl-1-piperazinyl)-4-phenyl-2-thiazolyl]- (9CI) (CA INDEX NAME)



RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT